Jim Trenkle

Associate Director, Commercial Planning Liver Disease
2016 - 2017
Pipeline Marketing Sciences for Hepatitis C and Liver Fibrosis Market research and forecasting for pipeline, inline, and external opportunity assets
Associate Director, Liver Disease Project and Portfolio Management
2014 - 2016
Expanding levels of responsibility and impact in each year, with Global Development strategy and execution responsibility for: • Complete Hepatitis C portfolio, including Sovaldi, Harvoni, SOF/VEL, and SOF/VEL/GS-9857 • Responsible for an aligned Liver Fibrosis company strategy. • Manage cross-functional teams and subteams: Clinical Research, Commercial Strategy, Clinical Operations, Regulatory Affairs, Process Chemistry and Manufacturing, and Medical Affairs
Sr Manager, Liver Disease Project and Portfolio Management
2010 - 2013
Managed ledipasvir and other hepatitis C compounds through development.
Research Scientist I/II, Medicinal Chemistry
2007 - 2010
Proven scientist with increasing title and responsibilities during my time in Research, with multiple successes in different therapeutic areas. • Three new chemical entities advanced into HCV clinical development. Two NCEs in Phase 2, one in Phase 3. One program in HIV advanced into clinic. • Collaborated heavily with biology, DMPK, structural chemistry, and formulation colleagues • Managed one direct report • Departmental ambassador

2002 - 2007

Graduate Research Assistant, Chemistry
2002 - 2007
PhD with Professor Tim Jamison in Organic Synthetic Chemistry. Single person total synthesis of complex natural product, the macrolide (–)-gloeosporone. Focus on organonickel, organocopper, alkyne, and epoxide chemistry.

2002 - 2002

Partner, Venture Investments at Novo Holdings